Navigation Links
Labopharm's Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria

- Product Now Being Sold in 14 Countries Worldwide -

LAVAL, QC, July 31 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its once-daily formulation of tramadol has been launched in the following countries:

South Korea - Labopharm's marketing partner for South Korea, WhanIn Pharmaceutical Co. Ltd., launched the product in July under the brand name TramaConti CR(R).

Australia - Labopharm's marketing partner for Australia, iNova Pharmaceuticals (Australia) Pty Limited launched the product in July under the brand name Durotram XR(R).

Romania - Labopharm's marketing partner for Romania, CSC Pharmaceuticals, launched the product in July under the brand name Noax(R) Uno.

Austria - Labopharm's marketing partner for Austria, CSC Pharmaceuticals, launched the product in June under the brand name Noax(R) Uno.

"With these launches, our once-daily tramadol product is now being sold in 14 countries that, combined, account for almost 55% of the world's market for tramadol products," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "South Korea and Australia, in particular, represent significant opportunities as the 6th and 12th largest markets for tramadol products in the world, respectively. We look forward to leveraging the experience we have gained through our previous European and Canadian launches and working with our marketing partners to maximize our product's potential in these markets."

Labopharm's product is available in 100mg, 200mg and 300mg dosage strengths in Australia, Austria and Romania and in 100mg and 200mg dosage strengths in South Korea. The 300 mg dosage strength is approved for sale in South Korea and may be marketed at a later date.

About Labopharm's Once-Daily Tramadol Product

Labopharm's once-daily tramadol product is based on the Company's proprietary Contramid(R) technology, which provides a dual matrix delivery system allowing both rapid and sustained drug release that maintains blood levels within the therapeutic range providing a full 24 hours of pain relief. The Company believes that maintaining drug concentrations within the therapeutic range has the advantage of fewer and less severe side effects while maintaining efficacy. Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 14 countries, including the five largest markets in Europe and Canada and is approved in 16 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distribution agreements in place for more than 50 markets globally.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Data Highlights Positive Results of Namenda (Memantine HCl) Once-Daily Extended-Release Formulation
2. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
3. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
4. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
5. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
6. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
7. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
8. Once-Daily Insulin Shot Proves Effective in Study
9. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
10. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood ... 2015. The research, which was conducted at the Dental Institute at King's College London ... between stress during pregnancy and future dental health in the child. For years, researchers ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading ... Singal's newly launched "Publish Academy" training course . Singal's new program, in ... enrollment today, and marketers around the Internet are weighing in with reviews. , ...
(Date:10/13/2015)... ... October 13, 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic ... or without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... in Seattle and the University of British Columbia found that certain genetic alterations were ...
(Date:10/13/2015)... ... October 13, 2015 , ... California Southern ... Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the renowned Johns ... spanned four decades. , Dr. McLeod’s long and successful nursing practice included a ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing ... people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and ... to breathe correctly, in concert with the 7,000 year old tradition they teach, ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  A minimally-invasive treatment just ... the United States.  After more than 10 years of ... 9 approved the use of High Intensity Focused Ultrasound ... cells while protecting surrounding tissue and minimizing chances for ... George Suarez , a pioneering Miami ...
(Date:10/13/2015)... , Oct. 13, 2015  ContraVir Pharmaceuticals, ... "Company"), a biopharmaceutical company focused on the development ... the closing of its previously announced underwritten public ... and warrants to purchase up to 3,000,000 shares ... combined price to the public of $3.00. The ...
(Date:10/13/2015)... -- Measurement in accountable care programs is essential for ... gaps in measurement can result in missed opportunities ... new, peer-reviewed study published in The ... measurement gaps for high-priority conditions and identifies ways ... --> "These gaps in measures present ...
Breaking Medicine Technology: